BRPI0814140A2 - composição de peptídeos associados a tumor e vacina anticâncer relacionada - Google Patents

composição de peptídeos associados a tumor e vacina anticâncer relacionada

Info

Publication number
BRPI0814140A2
BRPI0814140A2 BRPI0814140A BRPI0814140A BRPI0814140A2 BR PI0814140 A2 BRPI0814140 A2 BR PI0814140A2 BR PI0814140 A BRPI0814140 A BR PI0814140A BR PI0814140 A BRPI0814140 A BR PI0814140A BR PI0814140 A2 BRPI0814140 A2 BR PI0814140A2
Authority
BR
Brazil
Prior art keywords
tumor
cancer
peptide composition
associated peptide
related vaccine
Prior art date
Application number
BRPI0814140A
Other languages
English (en)
Inventor
Trautwein Claudia
Singh Harpreet
Schoor Oliver
Lewandrowski Peter
Walter Steffen
Weinschenk Toni
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority to BR122013005232-1A priority Critical patent/BR122013005232A2/pt
Publication of BRPI0814140A2 publication Critical patent/BRPI0814140A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0814140A 2007-07-27 2008-07-25 composição de peptídeos associados a tumor e vacina anticâncer relacionada BRPI0814140A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122013005232-1A BR122013005232A2 (pt) 2007-07-27 2008-07-25 Peptídeo; ácido nucleico ou vetor de expressão; célula hospedeira; método in vitro para produzir linfócitos t citotóxicos ativados; tais linfócitos; e usos

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07014796 2007-07-27
US95310907P 2007-07-31 2007-07-31
US98124107P 2007-10-19 2007-10-19
PCT/EP2008/006152 WO2009015841A1 (en) 2007-07-27 2008-07-25 Composition of tumour-associated peptides and related anti-cancer vaccine

Publications (1)

Publication Number Publication Date
BRPI0814140A2 true BRPI0814140A2 (pt) 2017-03-28

Family

ID=39926464

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814140A BRPI0814140A2 (pt) 2007-07-27 2008-07-25 composição de peptídeos associados a tumor e vacina anticâncer relacionada

Country Status (20)

Country Link
US (1) US7994276B2 (pt)
EP (2) EP2178557B1 (pt)
JP (2) JP5352586B2 (pt)
KR (1) KR101167392B1 (pt)
CN (2) CN101765434B (pt)
AU (1) AU2008281013B2 (pt)
BR (1) BRPI0814140A2 (pt)
CA (2) CA2694771A1 (pt)
DK (1) DK2567707T3 (pt)
EA (2) EA023928B1 (pt)
ES (1) ES2608583T3 (pt)
HU (1) HUE032379T2 (pt)
LT (1) LT2567707T (pt)
MX (1) MX2010001088A (pt)
NZ (1) NZ582823A (pt)
PL (1) PL2567707T3 (pt)
PT (1) PT2567707T (pt)
SI (1) SI2567707T1 (pt)
UA (2) UA117216C2 (pt)
WO (1) WO2009015841A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
NZ582823A (en) * 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
RU2633503C2 (ru) * 2011-10-28 2017-10-12 Онкотерапи Сайенс, Инк. Пептиды торк и содержащие их вакцины
EP2847322B1 (en) 2012-05-08 2019-06-26 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
CN104630145A (zh) * 2015-01-12 2015-05-20 杨世成 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11149087B2 (en) * 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201512703D0 (en) 2015-07-20 2015-08-26 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
CN105586312A (zh) * 2016-02-29 2016-05-18 时宏珍 Hla-a0201限制性抗muc-1抗原特异性ctl的制备方法
CN109922819A (zh) * 2016-09-27 2019-06-21 西莱克塔生物科技公司 用于治疗癌症的重组免疫毒素
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
CN110636855B (zh) * 2017-03-28 2024-08-09 俄亥俄州创新基金会 人pd1肽疫苗及其用途
CR20210160A (es) * 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
MA49123A (fr) * 2017-04-10 2020-03-25 Immatics Biotechnologies Gmbh Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
GB201810358D0 (en) * 2018-06-25 2018-08-08 Univ College Cardiff Consultants Ltd Cancer-specific t-cell receptors
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
WO2021019472A1 (en) * 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
CA3161242A1 (en) * 2019-12-18 2021-06-24 Birgitte Rono Nucleic acid vaccination using neo-epitope encoding constructs
CN111363009B (zh) * 2020-03-18 2020-10-30 北京鼎成肽源生物技术有限公司 一种直肠癌靶标抗原及其刺激培养的ctl细胞及其应用
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法
CN118955693A (zh) * 2024-07-30 2024-11-15 四川大学 抗纤维化的肽段、疫苗及其肽段疫苗的制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
JPH02107189A (ja) * 1988-05-25 1990-04-19 City Of Hope 癌胎児抗原フラグメント
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2217585T3 (es) 1997-10-10 2004-11-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea).
US6756038B1 (en) * 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
US6623923B1 (en) * 1998-12-23 2003-09-23 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030017167A1 (en) * 2000-06-09 2003-01-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020102544A1 (en) * 2000-09-15 2002-08-01 David Mack Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
EP1410035A2 (en) * 2000-12-08 2004-04-21 EOS Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
CA2459219A1 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2003224819A1 (en) * 2002-04-01 2003-10-20 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
US20030211477A1 (en) * 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
WO2004014867A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
EP1622937A2 (en) * 2003-05-05 2006-02-08 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Synthetic gene encoding human carcinoembryonic antigen and uses thereof
CN1727362B (zh) * 2004-07-30 2010-12-01 中国人民解放军第二军医大学 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
US20080254031A1 (en) 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
EP1642905B1 (en) * 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
ITRM20050064A1 (it) * 2005-02-16 2006-08-17 Univ Siena Peptide poliepitopico derivato dalla timidilato sintetasi avente attivita' immunologica e antitumorale e composizioni farmaceutiche relative.
EP1717245B1 (en) * 2005-04-26 2011-06-08 Immatics Biotechnologies GmbH T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
DE602005020046D1 (de) 2005-09-05 2010-04-29 Immatics Biotechnologies Gmbh Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
US8298544B2 (en) * 2006-02-27 2012-10-30 Gal Markel CEACAM based antibacterial agents
NZ582823A (en) * 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2009117656A2 (en) * 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
PT2119726E (pt) * 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano

Also Published As

Publication number Publication date
AU2008281013A1 (en) 2009-02-05
JP5352586B2 (ja) 2013-11-27
CN101765434B (zh) 2014-12-17
AU2008281013A2 (en) 2010-04-29
DK2567707T3 (en) 2017-07-31
MX2010001088A (es) 2010-06-01
WO2009015841A1 (en) 2009-02-05
EA201000208A1 (ru) 2011-02-28
KR101167392B1 (ko) 2012-07-19
EP2567707A3 (en) 2013-07-24
CN103360466B (zh) 2016-08-03
US20090148400A1 (en) 2009-06-11
LT2567707T (lt) 2017-01-10
UA117216C2 (uk) 2018-07-10
ES2608583T3 (es) 2017-04-12
EA018457B1 (ru) 2013-08-30
EP2178557B1 (en) 2017-03-01
AU2008281013B2 (en) 2012-06-28
HK1182923A1 (en) 2013-12-13
JP2013165721A (ja) 2013-08-29
NZ582823A (en) 2012-04-27
US7994276B2 (en) 2011-08-09
SI2567707T1 (sl) 2017-01-31
CN101765434A (zh) 2010-06-30
EP2567707A2 (en) 2013-03-13
HUE032379T2 (en) 2017-09-28
JP2010534627A (ja) 2010-11-11
EA201300322A1 (ru) 2013-10-30
KR20100040875A (ko) 2010-04-21
CA2817054C (en) 2017-02-28
PL2567707T3 (pl) 2017-03-31
EP2567707B1 (en) 2016-10-05
JP5746251B2 (ja) 2015-07-08
CA2694771A1 (en) 2009-02-05
PT2567707T (pt) 2016-12-27
EP2178557A1 (en) 2010-04-28
UA103882C2 (uk) 2013-12-10
EA023928B1 (ru) 2016-07-29
CN103360466A (zh) 2013-10-23
CA2817054A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
PL2567707T3 (pl) Kompozycja peptydów związanych z guzem i pokrewna szczepionka przeciw rakowi
LTPA2020523I1 (lt) Anti-CD79b antikūnai ir imunokonjugatai ir jų panaudojimo būdai
IL200478A (en) Kif20a-derived peptide compounds
PL2341927T3 (pl) Kompozycja obejmująca peptydy związane z nowotworem i szczepionka do leczenia glejaka i innych nowotworów
RU2448708C3 (ru) Противоопухолевое средство против рака щитовидной железы
EP2093287A4 (en) PEPTIDE BINDER IGG
HUE035983T2 (hu) Készítmény és terápiás tumorellenes oltóanyag
ZA201104497B (en) Peptide therapeutic conjugates and uses thereof
BRPI1014998A2 (pt) peptídio auxiliador de antígeno de câncer
GB0718167D0 (en) Cancer marker and therapeutic target
LTC2502996I2 (lt) Anti-FGF23 antikūnas ir jį apimanti farmacinė kompozicija
EP2006377A4 (en) NEW TUMORANT PEPTIDES
HUE039385T2 (hu) ABCB5 rákterápiás célzása
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
HUE038563T2 (hu) Rák kezelési eljárás
EP2346531A4 (en) ANTITUMOR VACCINE
FI20070508A0 (fi) Peptidisubstraatti ja sen käyttö
EP2363468A4 (en) TUMORANTIGENPEPTID AND USE THEREOF
BRPI0815772A2 (pt) Tratamento de câncer de pulmão
FI20075483A0 (fi) Uusi peptidi
EP2155241A4 (en) PREVENTION OF CANCER BY IMMUNIZING
DK2227486T3 (da) Peptidanaloger og konjugater dermed
FI20065208A0 (fi) Peptidikonjugaatteja
GB0722773D0 (en) Cancer markers and uses thereof
GB0707417D0 (en) Cancer markers and uses thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2472 DE 22-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.